Japan’s Takeda Pharmaceutical Co., Ltd has inaugurated its R&D Asia-Pacific headquarters in Pudong, Shanghai. The new site will serve as the firm’s Asian drug development center, marking an upgrade to its China R&D strategy.
China Strategy
Takeda launched a major China strategy in 2022 aimed at increasing R&D investment and accelerating new drug development. The goal is for China to become the company’s second-largest market by 2030. The Shanghai R&D center will enhance integration with the biopharma industry cluster in Pudong’s Zhangjiang area.
Core Functions
The Shanghai site will focus on innovation through collaborations with local partners, supporting Takeda’s efforts to develop new drugs tailored for the Chinese market.-Fineline Info & Tech
